Acalabrutinib - Acerta Pharma/AstraZeneca
Alternative Names: Acalabrutinib maleate; ACP-196; CALQUENCE; CalquenceLatest Information Update: 18 Jun 2024
At a glance
- Originator Acerta Pharma
- Developer Acerta Pharma; AstraZeneca; Biologics Inc; National Institutes of Health (USA)
- Class Anti-infectives; Antineoplastics; Antirheumatics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Phase III Diffuse large B cell lymphoma
- Phase II B-cell lymphoma; Bladder cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Phase I/II B-cell prolymphocytic leukaemia; Follicular lymphoma; Glioblastoma; Multiple myeloma
- Phase I Infections
- Discontinued COVID 2019 infections; Haematological malignancies; Rheumatoid arthritis
Most Recent Events
- 17 Jun 2024 Efficacy and adverse events data from a phase III ECHO trial in Mantle cell lymphoma released by AstraZeneca
- 16 Jun 2024 Efficacy and adverse event data from the phase III ECHO trial in Mantle cell lymphoma released by AstraZeneca
- 02 May 2024 Efficacy and adverse event data from the phase III ECHO trial in Mantle cell lymphoma released by AstraZeneca